PANADOL® EXTRA

PRODUCT INFORMATION

DESCRIPTION

Active Ingredients: Paracetamol 500 mg and Caffeine 65 mg

Caplet Excipients: Maize starch
Starch - Pregelatinised maize
Povidone
Potassium sorbate
Purified talc
Stearic Acid
Crocarmellose sodium
Hypermellose
Glycerol triacetin

Soluble Tablet Excipients: Sorbitol
Saccharin sodium
Sodium bicarbonate
Povidone
Sodium lauryl sulphate
Dimethicone 350
Citric acid (anhydrous)
Sodium carbonate (anhydrous)

Optizorb® Formulation: Starch - Pregelatinised maize
Caplet Excipients: Calcium carbonate
Alginic acid
Crocspovidone
Povidone
Magnesium stearate
Parahydroxybenzoates (sodium methyl, sodium ethyl, sodium propyl)
OPADRY complete film coating system YS-1-7003 WHITE
Carnauba wax
Water – purified

Contains no sugar, lactose or gluten.
Paracetamol is a para-aminophenol derivative that exhibits analgesic and antipyretic activity. It inhibits prostaglandin synthetase in the hypothalamus, prevents synthesis of spinal prostaglandin and inhibits inducible nitric oxide synthesis in macrophages. Paracetamol has minimal anti-inflammatory action. Caffeine acts as an analgesic adjuvant which enhances the efficacy of paracetamol.

Pharmacodynamics
A meta-analysis to determine the analgesic effect of the combined dosage of paracetamol (1,000 mg) and caffeine (130 mg) versus paracetamol (1,000 mg) alone has been undertaken. The primary outcome of the meta-analysis was to determine whether the use of paracetamol plus caffeine provided significantly superior analgesia over paracetamol alone in acute pain states.

Inclusion criteria were full journal publications reporting the results of randomised, controlled, double-blind trials comparing the two treatments.

The clinical measure selected was the >50% maxTOTPAR (i.e. the number of patients in the two groups who achieved at least 50% of the maximal pain relief). The dichotomous descriptor of >50% maxTOTPAR was chosen because it is a simple clinical end point of half pain relieved. It is a well-defined clinical measure of pain relief and can be used to evaluate the comparative benefit of contrasting medications.

Of the seven papers describing double blind trials, four papers met the inclusion criteria for the meta-analysis and contained eight separate studies. These eight studies spanned a number of different pain states; post-partum pain (n=3), headache (n=2), dental pain (n=2) and dysmenorrhoea (n=1).

All of the eight studies included in the meta-analysis provided efficacy results as mean TOTPAR values over 0-4-hours. The total number of patients evaluated was 1265 (paracetamol plus caffeine) and 1268 (paracetamol alone). Using the end-point of at least half pain relief achieved (at least 50%maxTOTPAR), the odds ratio of a greater likelihood of effect of the paracetamol/caffeine combination compared to paracetamol alone is 1.34 (95% CI 1.14, 1.58). This corresponds to a relative benefit of 1.12 (95% CI 1.05-1.19). Analgesic efficacy has also been determined as the number
needed to treat (NNT). For the comparison of the paracetamol/caffeine combination with paracetamol alone, the NNT for at least 50% pain relief achieved over 0-4 hours is 14.

Compared with placebo, the relative benefit for the paracetamol/caffeine combination is 1.42 (95%CI 1.29-1.56) and the NNT for at least 50% pain relief achieved over 0-4 hours is 5. For paracetamol alone compared with placebo, the relative benefit is 1.27 (95%CI 1.15-1.40) and the NNT is 81.

The meta-analysis indicated that the combination of paracetamol and caffeine has an added benefit in analgesic activity compared to paracetamol alone.

Time effect curves for pain relief were presented in all eight of the studies included in the meta-analysis. Overall, these studies suggested that combining paracetamol with caffeine results in an earlier analgesic effect than is achieved with paracetamol alone.

**Pharmacokinetics**

After oral administration, paracetamol is absorbed rapidly and completely from the gastrointestinal tract; peak plasma levels occur 10 to 60 minutes after administration.

Paracetamol is uniformly distributed throughout most body fluids; the apparent volume of distribution is 1 to 1.2 L/kg. Paracetamol can cross the placenta and is excreted in breast milk. Plasma protein binding is negligible at usual therapeutic concentrations but increases with increasing concentrations.

Paracetamol is metabolised by the hepatic microsomal enzyme system. In adults at therapeutic doses, paracetamol is mainly conjugated with glucuronide (45 to 55%) or sulfate (20 to 30%). A minor proportion (less than 20%) is metabolised to catechol derivatives and mercapturic acid compounds via oxidation. Paracetamol is excreted in the urine mainly as the glucuronide and sulfate conjugates. Less than 5% is excreted as unchanged paracetamol with 85 to 90% of the administered dose eliminated in the urine within 24 hours of ingestion. The elimination half-life varies from 1 to 3 hours. Food intake delays paracetamol absorption.

Caffeine is absorbed readily after oral administration. Maximal plasma concentrations are achieved in adults within one hour and the plasma half-life is about 3 to 7 hours. Caffeine is almost completely metabolised in the liver by oxidation, demethylation and acetylation to various xanthine derivatives, which are excreted in the urine.

Regular PANADOL EXTRA caplets and Panadol tablets are bioequivalent for AUC0-10hr and Cmax for paracetamol. The extent of absorption (AUC) and peak plasma levels (Cmax) of paracetamol were similar for both products. The time

---

to peak plasma level ($t_{\text{max}}$) was not significantly different for regular PANADOL EXTRA caplets and Panadol tablets.

For PANADOL EXTRA soluble tablets the $t_{\text{max}}$ for both paracetamol and caffeine was reached twice as fast (0.27 h, 0.32 h respectively) compared to regular PANADOL EXTRA caplets (0.67 h, 0.65 h respectively) ($p \leq 0.043$).

PANADOL EXTRA with Optizorb Formulation caplets contain a disintegrant system which optimises tablet dissolution compared to regular PANADOL EXTRA caplets.

Human pharmacokinetic data demonstrate that paracetamol and caffeine from PANADOL EXTRA with Optizorb Formulation caplets showed faster and greater absorption in the first 60 minutes ($T_{\text{max}}$, $\text{AUC}_{0-30\text{min}}$ and $\text{AUC}_{0-60\text{min}}$) compared to regular PANADOL EXTRA caplets.

Maximum plasma concentration of paracetamol is reached faster for PANADOL EXTRA with Optizorb Formulation caplets compared to regular PANADOL EXTRA Caplets in fasted and fed states ($p < 0.01$). PANADOL EXTRA with Optizorb Formulation caplets achieved $t_{\text{max}}$ in the fasted state in a faster median time of 0.50 hrs versus 0.99 hrs for regular PANADOL EXTRA. After food, PANADOL EXTRA with Optizorb Formulation caplets achieved $t_{\text{max}}$ in a faster median time of 1.00 hrs versus 1.25 hours for regular PANADOL EXTRA Caplets.

Total extent of absorption of paracetamol and caffeine from PANADOL EXTRA with Optizorb Formulation caplets is equivalent to that from regular PANADOL EXTRA Caplets ($\text{AUC}_{0-\infty}$ and $\text{AUC}_{0-t}$).

**INDICATIONS**

PANADOL EXTRA is indicated for the temporary relief of pain and discomfort associated with headache, tension headache, migraine headache, osteoarthritis, arthritis, cold & flu symptoms, toothache, dental procedures, muscular aches, sore throat and period pain. Reduces fever.

**CONTRAINDICATIONS**

This product is contraindicated in patients with hypersensitivity to paracetamol, caffeine or to any of the excipients.

**PRECAUTIONS**

Contains paracetamol. Do not use with any other paracetamol-containing products. The concomitant use with other products containing paracetamol may lead to an overdose.
Paracetamol overdose may cause liver failure which can lead to liver transplant or death.

Paracetamol should be used with caution in patients with:

- Impaired liver function: Underlying liver disease increases the risk of paracetamol-related liver damage
- Impaired kidney function: Administration of paracetamol to patients with moderate to severe renal impairment may result in accumulation of paracetamol conjugates.

Excessive intake of caffeine (e.g. coffee, tea and some canned drinks) should be avoided while taking this product.

Each PANADOL EXTRA soluble tablet contains 426 mg of sodium per tablet (854 mg of sodium per 2 tablet dose). To be taken into consideration by patients on a controlled sodium diet.

Each PANADOL EXTRA soluble tablet contains sorbitol powder (E420) at 50 mg per tablet. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

Cases of hepatic dysfunction/failure have been reported in patients with depleted glutathione levels, such as those who are severely malnourished, anorexic, have a low body mass index or are chronic heavy users of alcohol.

In patients with glutathione depleted states such as sepsis, the use of paracetamol may increase the risk of metabolic acidosis.

If symptoms persist, medical advice must be sought.

Keep out of sight and reach of children.

**Use in Pregnancy**

Pregnancy Category A – Both Paracetamol and Caffeine have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations.

Animal studies have shown an association between caffeine intake and foetal abnormalities, but only at very high doses that are not considered relevant to human consumption.

There is limited evidence that maternal caffeine intake during pregnancy may reduce birth weight. One review article indicated a correlation between caffeine consumption during pregnancy and a decrease in birth weight due to the vasoconstrictive effect of caffeine on placental circulation. Other reviews have found no correlation between caffeine intake in pregnancy and birth weight.
Paracetamol-caffeine is not recommended for use during pregnancy due to the possible increased risk of spontaneous abortion associated with caffeine consumption.

**Use in Lactation**
Paracetamol is excreted in breast milk. The amount available for ingestion by the infant has been reported variously as less than 0.1% of a single dose of paracetamol 500 mg and as 0.04 to 0.23% of a single 650 mg dose. Maternal ingestion of paracetamol in usual analgesic doses does not appear to present a risk to the breastfed infant.

Caffeine is excreted in breast milk. Studies examining the transfer of caffeine into breast milk after oral doses of 35 to 336 mg of caffeine have recorded peak maternal plasma concentrations of 2.4 to 4.7 micrograms/mL, peak maternal saliva concentrations of 1.2 to 9.2 micrograms/mL, and peak breast-milk concentrations of 1.4 to 7.2 micrograms/mL. At these concentrations in breast milk, the calculated daily caffeine ingestion by breast-fed infants ranged from 1.3 to 3.1 mg, which was not thought to present a hazard, although irritability and a poor sleeping pattern have been reported.

The American Academy of Pediatrics states that caffeine is excreted slowly by the infant and may be associated with irritability and poor sleeping pattern when ingested by breast-feeding mothers. However, no effects occur with moderate intake of caffeinated beverages (2 to 3 cups daily) and caffeine is usually compatible with breast feeding.

**Use in Children**
Not recommended in children under the age of 12 years.

**Effects on ability to drive and use machinery**
PANADOL EXTRA has no influence on the ability to drive or use machines.

**INTERACTIONS**
The anticoagulant effect of warfarin and other coumarins can be enhanced by prolonged regular daily use of paracetamol with an increased risk of bleeding; occasional doses have no significant effect. Paracetamol absorption is increased by drugs which increase gastric emptying, eg metoclopramide, and decreased by drugs which decrease gastric emptying, eg propantheline, antidepressants with anticholinergic properties, narcotic analgesics. Paracetamol may increase chloramphenicol concentrations. The likelihood of paracetamol toxicity may be increased by the concomitant use of enzyme inducing agents such as alcohol or anticonvulsant drugs.

Paracetamol excretion may be affected and plasma concentrations altered when given with probenecid.

Colestyramine reduces the absorption of paracetamol if given within 1 hour of paracetamol.
Caffeine undergoes extensive metabolism by hepatic microsomal cytochrome P450 isoenzyme CYP1A2, and is subject to numerous interactions with other drugs and substances which enhance or reduce its metabolic clearance.

No potentially hazardous interactions with caffeine have been reported. However patients who take medicines that decrease caffeine elimination may need to limit caffeine intake to avoid adverse events.

ADVERSE EFFECTS

Events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by System Organ Class and frequency.

The following convention has been utilised for the classification of undesirable effects: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (<1/10,000), not known (cannot be estimated from available data)

Adverse event frequencies have been estimated from spontaneous reports received through post marketing data.

<table>
<thead>
<tr>
<th>Body System</th>
<th>Undesirable Effect</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paracetamol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Thrombocytopenia</td>
<td>Very rare</td>
</tr>
<tr>
<td>Immune System disorders</td>
<td>Anaphylaxis</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Cutaneous hypersensitivity reactions including skin rashes, angioedema, Stevens Johnson Syndrome</td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Bronchospasm, especially in patients sensitive to aspirin and other NSAIDs</td>
<td>Very rare</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>Hepatic dysfunction</td>
<td>Very rare</td>
</tr>
<tr>
<td>Caffeine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central Nervous system</td>
<td>Nervousness</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td></td>
</tr>
</tbody>
</table>

When the recommended PANADOL EXTRA dosing regimen is combined with dietary caffeine intake, the resulting higher dose of caffeine may increase the potential for caffeine-related adverse effects such as insomnia, restlessness, anxiety, irritability, headaches, gastrointestinal disturbances and palpitations.
DOSAGE AND ADMINISTRATION

Caplets and Optizorb Formulation caplets – PANADOL EXTRA caplets are to be administered orally, with or without food. For Adults and children 12 years and older: 2 caplets every 4 to 6 hours (as required) with water. Maximum of 8 caplets in 24 hours. Not recommended in children under the age of 12 years.

Soluble Tablets – PANADOL EXTRA soluble tablets are to be administered orally, with or without food. For Adults and children 12 years and older: 2 soluble tablets every 4 to 6 hours (as required). Maximum of 8 Soluble tablets in 24 hours. Not recommended in children under the age of 12 years. PANADOL EXTRA soluble tablets should be dissolved in at least half a glass of water.

The lowest dose necessary to achieve efficacy should be used. Do not exceed the stated dose. PANADOL EXTRA should not be used with other paracetamol containing products.

OVERDOSAGE

Paracetamol overdose may cause liver failure which can lead to liver transplant or death.

Immediate medical management is required in the event of overdose, even if symptoms of overdose are not present.

Administration of N-acetylcysteine may be required.

If an overdose is taken or suspected, the Poisons Information Centre should be contacted immediately for advice (call 131 126), or the patient should go to a hospital straight away, even if they feel well, because of the risk of delayed, serious liver damage. See Adverse Effects.

Caffeine overdose is rare. Early symptoms include insomnia, restlessness, excitement and may progress to mild delirium.

PRESENTATION AND STORAGE CONDITIONS

Caplets - White film coated, capsule-shaped tablet (caplet) with flat edges. “PANADOL EXTRA” is embossed on one face of the caplet. Packs of 10, 18, 36, 64 and 72 caplets.

Soluble Tablets - Flat, white tablets with bevelled edges, packed in a laminate strip. They effervesce vigorously when placed in water and dissolve to give a clear, odourless solution with a slightly sweet taste. Pack of 24 soluble tablets.
Optizorb Formulation Caplets – White to off-white, oval shaped film coated tablet, debossed with a logo “P” in a circle on one side and a deep score line on the other side. Packs of 20 and 40 caplets.

Store below 25 degrees Celsius. Keep out of reach of children.

NAME AND ADDRESS OF THE SPONSOR

GlaxoSmithKline Consumer Healthcare
82 Hughes Avenue
ERMINGTON NSW 2115

POISON SCHEDULE OF THE MEDICINE

S2 Pharmacy Medicine

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (THE ARTG)

13.10.2009

DATE OF THE MOST RECENT AMENDMENT

17 NOV 2015

PANADOL, OPTIZORB and device are registered trade marks of the GSK group of companies or its licensor.